Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05827081
Other study ID # CLEE011O12001
Secondary ID
Status Suspended
Phase Phase 3
First received
Last updated
Start date February 28, 2024
Est. completion date September 20, 2030

Study information

Verified date April 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, multicenter, phase IIIb, single-arm study to evaluate the safety and efficacy of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a wide patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, II (subset) or I (high-risk subset as exploratory cohort) early Breast Cancer (EBC)


Recruitment information / eligibility

Status Suspended
Enrollment 3100
Est. completion date September 20, 2030
Est. primary completion date September 7, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer - Participant has HER2-negative breast cancer - Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene, at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and the participant should have at least 3 years remaining of endocrine adjuvant therapy. For participants with prior ET treatment > 12 months, the investigator should rule out disease recurrence prior to enrollment. The number of participants with prior ET between 12 and 36 months will be capped at 1000. - Participant has no contraindication for the adjuvant ET in the study. - Participant after complete surgical resection with the final surgical specimen microscopic margins free from tumor and in one of below categories: - Anatomic Stage Group III - Anatomic Stage Group II (subset) - Anatomic Stage Group I (high-risk subset as exploratory cohort) - Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1 or 2. - Participant has adequate bone marrow and organ function. Key Exclusion Criteria: - Participant with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery. - Participant is concurrently using other anti-neoplastic therapy with the exception of adjuvant ET. - Participant has any other concurrent severe and/or uncontrolled medical condition - Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality. - Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial. Other inlcusion/exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ribociclib
Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
Letrozole
Letrozole 2.5 mg orally once daily continuously
Ansastrozole
Anastrozole 1 mg orally once daily continuously.
Goserelin
Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
Leuprolide
Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
Exemestane
Exemestane 25 mg once daily continuously

Locations

Country Name City State
Australia Novartis Investigative Site Gateshead New South Wales

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years iBCFS is defined as the time from the date of first dose to the date of the first event of invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence, death (any cause), or contralateral invasive BC. iBCFS will be assessed using STEEP criteria version 2.0 (Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials), as assessed by Investigator.
The iBCFS rate at 3 years will be assessed.
At 3 years
Secondary Invasive Disease-Free Survival (iDFS) iDFS is defined as the time from the date of first dose of study treatment to the date of the first event of invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence, death (any cause), contralateral invasive BC, or second primary non-breast invasive cancer (excluding basal and squamous cell carcinomas of the skin). iDFS will be assessed using STEEP 2.0 as assessed by the investigator. Up to approximately 6 years
Secondary Distant Relapse-Free Survival (DRFS) Distant Relapse Free Survival (DRFS) is defined as the time from the date of first dose of study treatment to the date of the first event of recurrence at a distant site or death (any cause). DRFS will be assessed using STEEP 2.0 as assessed by the investigator. Up to approximately 6 years
Secondary Recurrence-Free Interval (RFI) RFI is defined as the time from date of first dose to date of first event of invasive recurrence in the ipsilateral breast or locoregionally, at a distant site, or death from breast cancer. RFI will be assessed using STEEP 2.0 as per investigator assessment. Up to approximately 6 years
Secondary Relative dose intensity (RDI) of ribociclib RDI is defined as the ratio of the dose intensity delivered to the planned dose intensity. Up to 3 years
Secondary Overall Survival (OS) OS is defined as time from the start of study treatment to date of death due to any cause. Up to approximately 6 years
Secondary Time To Discontinuation (TTD) of ribociclib TTD is defined as the time from starting ribociclib to the time to treatment discontinuation due to any cause. Up to 3 years
Secondary Changes from baseline in Functional Assessment of Cancer Therapy - Breast (FACT-B) score The FACT-B is a questionnaire that consists of 37 items with items from FACT-General (FACT-G) questionnaire (27 items) and from the Breast Cancer Subscale (BCS, 10 items). FACT-B consists of five subscales that address different aspects of the participant's quality of life: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and BCS. Up to approximately 6 years
Secondary Changes from baseline in Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) score The FACT-ES is a questionnaire that consists of 19 items which assesses endocrine complaints and adverse events. Up to approximately 6 years
Secondary Changes from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score The FACIT-F is a 13-item questionnaire designed to assess self-reported fatigue and its impact on daily activities and functions. Up to approximately 6 years
Secondary Changes from baseline in European Quality of Life-5 Dimensions (EQ-5D-5L) score EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D-5L health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Up to approximately 6 years
Secondary Changes from baseline in Work Productivity and Activity Impairment Questionnaire (WPAI-GH) score WPAI-GH measures the impact of health problems on the participant's productivity, in paid or unpaid activities, in the last 7 days. It is 6-item scale measuring absenteeism, presenteeism, and impairments in unpaid activity. Up to approximately 6 years
See also
  Status Clinical Trial Phase
Withdrawn NCT04538833 - GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel Phase 2
Completed NCT04436744 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) Phase 2
Completed NCT02187744 - A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) Phase 3
Terminated NCT01155063 - Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients N/A
Recruiting NCT03949634 - Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD) Phase 3
Active, not recruiting NCT05730647 - Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
Terminated NCT01919229 - A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Phase 2
Active, not recruiting NCT04293393 - Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients Phase 2
Completed NCT00713141 - Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer N/A
Recruiting NCT06341894 - Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer Phase 2
Not yet recruiting NCT06404736 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer Phase 2
Not yet recruiting NCT06404463 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer Phase 2
Not yet recruiting NCT06435104 - Aromatherapy in the Treatment of Early Breast Cancer Phase 2
Recruiting NCT03520894 - Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer N/A
Completed NCT03786198 - Activity Program During Aromatase Inhibitor Therapy N/A
Completed NCT01613352 - Feasibility of Ambulatory Surgery for Early Breast Cancer N/A
Completed NCT02738970 - A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC) Phase 1
Recruiting NCT01792726 - A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer. N/A
Completed NCT00323479 - Arthralgia During Anastrozole Therapy for Breast Cancer Phase 4
Completed NCT03493854 - A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Phase 3